Therapeutic vaccine for lymphoma.
The unique antigenic determinants (Idiotype [Id]) of the immunoglobulin expressed on a given B-cell malignancy can serve as a tumor-specific antigen for active immunotherapy. Therapeutic vaccines targeting the tumor-specific idiotype have demonstrated promising results against lymphomas in phase I/II studies and are currently being evaluated in phase III randomized trials. Additional vaccine therapies being developed include those based on DNA, dendritic cells, gene-modified tumor cells. It is hoped that immunotherapeutic agents, used in tandem or in combination, may in the future allow effective treatment of lymphoid malignancies and delay or even replace the need for conventional cytotoxic therapies.
Lee
Seung-Tae
ST
Department of Lymphoma and Myeloma, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Neelapu
Sattva S
SS
Kwak
Larry W
LW
D019496:Cancer Vaccines / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*
D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes